sellWeak cluster of 610b5-1 plan
Henry E. Pelish sold $502k of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 5,160 shares at an average of $97.24, traded Jan 5, 2026, filed Jan 7, 2026.
Warning score
28Value
$502k
5,160 shares
Holdings after
65,888
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +18Trade size$502k at market
- 0Share of holdings soldSold 7.3% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-26-006576, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -513 | $96.06 | $49k | 70,535 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -660 | $96.85 | $64k | 69,875 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,137 | $97.96 | $111k | 68,738 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -186 | $98.52 | $18k | 68,552 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,106 | $96.75 | $107k | 67,446 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -1,369 | $97.33 | $133k | 66,077 | Jan 7, 2026 |
| Jan 6, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -189 | $98.40 | $19k | 65,888 | Jan 7, 2026 |
| Jan 7, 2026 | AGrant or award Class A Common Stock10b5-1 | +17,500 | $0.00 | $0 | 83,388 | Jan 7, 2026 |
| Jan 7, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +17,500 | $0.00 | $0 | 17,500 | Jan 7, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.